Filing summary
Entity mismatch: The request identifies Accendra Health Inc., but the supplied 10-Q is for Owens & Minor, Inc. This summary reflects the filing provided, not an Accendra Health filing.
Business context and reporting period
Unaudited results cover the three months ended March 31, 2021, compared with the three months ended March 31, 2020. Owens & Minor operates Global Solutions, including U.S. distribution and outsourced logistics, and Global Products, which manufactures and sources medical-surgical products. The 2020 comparison excludes Movianto, divested in June 2020, from continuing operations.
Financial performance and liquidity
| Metric | Q1 2021 | Q1 2020 |
|---|---|---|
| Net revenue | $2,326.5 million | $2,122.7 million |
| Gross margin | $442.8 million; 19.03% of revenue | $268.6 million; 12.65% of revenue |
| Operating income | $146.7 million | $10.8 million |
| Net income (loss) | $69.6 million | $(11.3) million |
| Diluted earnings (loss) per share | $0.98 | $(0.19) |
| Operating cash flow | $25.4 million | $93.5 million |
Revenue increased 9.6%. Global Products revenue rose 68.4% to $658.8 million, while Global Solutions revenue was nearly flat at $1,849.5 million. Management attributed the improvement in gross margin and operating income to PPE demand, favorable product mix, timing of cost changes, manufacturing output, and operating efficiencies. Interest expense fell to $13.7 million from $23.3 million.
Q1 cash used in investing activities was $6.6 million and cash used in financing activities was $80.4 million; cash, cash equivalents and restricted cash decreased $63.7 million to $70.8 million. Working capital absorbed cash, including a $89.4 million increase in inventories and a $45.9 million use from accounts receivable. At March 31, cash and cash equivalents were $54.5 million; current assets were $2,206.7 million and current liabilities were $1,337.3 million.
Total debt was $982.4 million, including $981.3 million of long-term debt. The company reported $282 million available under its $300 million revolving facility and stated it was in compliance with debt covenants. Total assets were $3,390.8 million and total equity was $786.3 million at quarter-end.
Material changes and unusual items
- Operating income improvement was concentrated in Global Products: segment operating income increased to $163.6 million from $18.6 million; Global Solutions segment operating income rose to $8.9 million from $7.7 million.
- Q1 2021 included a $40.4 million loss on extinguishment of debt, comprising $15.3 million of financing-cost and fee write-offs and $25.1 million reclassified from accumulated other comprehensive loss after terminating interest-rate swaps. The 2020-period charge was $4.1 million.
- In March 2021, the company issued $500 million of 4.5% senior notes due 2029, repaid its prior term loans and reduced revolving borrowings. Its new revolving credit agreement matures in March 2026; the receivables securitization program, with a maximum $450 million outstanding, matures in March 2024.
- DS&A expenses increased 15.2% to $292.7 million. Exit and realignment charges were $6.0 million, including costs related to Fusion5 retained assets, IT restructuring, and organizational realignment.
- Common shares outstanding increased to 75.1 million from 73.5 million at year-end 2020. The company had not issued shares under its $50 million at-the-market program as of March 31.
Outlook, risks, and contingencies
The filing provides no specific financial guidance. Management said PPE demand and expanded production supported Q1 results but cautioned that pandemic-related sales growth and operating improvements may not persist. COVID-19 continued to affect elective procedures and demand patterns. The company cited uncertainty around the pandemic, competition and pricing, customer and supplier dependence, raw-material costs (including polypropylene and nitrile), foreign exchange, fuel prices, interest rates, financing access, and execution of operational initiatives.
The company disclosed an IRS proposed adjustment concerning its 2015 and 2016 tax returns and transfer-pricing treatment. Management disagrees with the IRS position, believes reserves are adequate, and does not expect a material impact, but noted an adverse outcome could materially affect results or cash flows. Debt agreements contain cross-default provisions and require leverage and interest-coverage covenant compliance. The company estimated that a 100-basis-point interest-rate increase would reduce annual pretax earnings by about $2.5 million based on quarter-end borrowings.
Important facts for investors to verify
- Confirm the intended issuer: the provided filing is Owens & Minor, Inc., not Accendra Health Inc.
- Assess whether elevated PPE demand, Global Products margins, and manufacturing efficiencies are sustainable as pandemic-related demand changes.
- Track operating cash conversion and working capital, particularly inventory days, DSO, and receivables collections.
- Review the debt refinancing, maturity schedule, covenant headroom, variable-rate exposure, and potential effects of cross-default provisions.
- Monitor the IRS tax dispute and any further costs related to Fusion5 retained assets or restructuring.